The role and regulation of urokinase-type plasminogen activator receptor gene expression cancer invasion and metastasis

Medicinal Research Reviews

Volumn 21, Issue 2, 2001, Pages 146-170

  Wang, Yao ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cancer metastasis; Urokinase receptor and gene regulation

Indexed keywords

COMPLEMENTARY DNA; GLYCOPROTEIN; MESSENGER RNA; TRANSCRIPTION FACTOR; UROKINASE RECEPTOR;

CANCER INVASION; EXTRACELLULAR MATRIX; GENE CONTROL; GENE EXPRESSION; GENETIC ORGANIZATION; GENETIC TRANSCRIPTION; GENOME; HUMAN; METASTASIS; MOLECULAR CLONING; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN DOMAIN; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; PLASMINOGEN ACTIVATORS; PROMOTER REGIONS (GENETICS); RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 0035127868     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-1128(200103)21:2<146::AID-MED1004>3.0.CO;2-B     Document Type: Review

References (125)

1. Biology and biochemistry of proteinases in tumor invasion
2. One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity
3. Structure and function of the urokinase receptor
4. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody
5. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli
6. The human tissue plasminogen activator gene
7. Plasminogen activators, tissue degradation and cancer
8. Basic and clinical aspects of fibrinolysis and thrombolysis
9. Physiological consequences of loss of plasminogen activator gene function in mice
10. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility
11. Generation and characterization of urokinase receptor-deficient mice
12. A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification
13. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase
14. Increase in urokinase plasminogen activator mRNA synthesis in human carcinoma cells is a primary effect of the potent tumor promoter, phorbol myristate acetate
15. Urokinase receptors in human monocytes
16. The receptor-binding sequence of urokinase
17. Plasminogen activation initiated by single chain urokinase-type plasminogen activator: Potentiation by U937 cells
18. Complementation analysis of extracellular matrix degradation: Enhancement of urokinase plasminogen activation by the urokinase receptor
19. The human receptor for urokinase plasminogen activator. NH2-terminal acid sequence and glycosilation variants
20. Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator
21. Domain 1 of the urokinase receptor (uPAR) is required for uPAR-mediated cell binding to vitronectin
22. Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom neurotoxins
23. Removal of domain D2 or D3 of the human urokinase receptor does not affect ligand affinity
24. Purified α2-macroglobulin receptor/LDL receptor-related protein binds urokinase-plasminogen activator inhibitor type I complex. Evidence that the α2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes
25. Urokinase/urokinase receptor system: Internalization/degradation of urokinase-serpin complexes: Mechanism and regulation
26. LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation
27. Urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen-activator receptor in THP-1 cells
28. Urokinase-type plasminogen activator and its receptor: New targets for anti-metastatic therapy?
29. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis
30. Chromosomal localization of the human urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 genes. Implications in colorectal cancer
31. Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract
32. Molecular cloning of cDNA for the bovine urokinase-type plasminogen activator receptor
33. Bovine urokinase-type plasminogen activator and its receptor: Cloning and induction by retinoid acid
34. Isolation and characterization of multiple isoforms of the rat urokinase receptor in osteoblasts
35. Structure of the human urokinase receptor gene and its similarity to CD59 and the Ly-6 family
36. Localization of the disufide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins
37. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer
38. An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator
39. uPA, uPAR, PAI-1: Key intersection of proteolytic, adhesive and chemotactic highways?
40. Receptor mediated binding of the fibrinolytic components, plasminogen and urokinase to peripheral blood cells
41. Upregulation of urokinase receptor expression on migrating endothelial cells
42. Regulation of the endothelial cell urokinase-type plasminogen activator receptor, evidence for cyclic AMP-dependent and protein kinase C-dependent pathways
43. The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils
44. Urokinase receptor, an activation antigen in human T lymphocytes
45. Function of the urokinase receptor (CD87) in neutrophil chemotaxis
46. Production of second messengers following chemotactic and mitogenic urokinase-receptor interaction in human fibroblasts and mouse fibroblasts transfected with human urokinase receptor
47. Biosynthesis and apical localization of the urokinase receptor in polarized MDCK epithelial cells
48. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activators to a specific receptor on U937 monocytes
49. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines
50. Decreased urokinase receptor expression by overexpression of the plasminogen activator in a colon cancer cell line
51. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody
52. Human urokinase receptor expression is inhibited by amiloride and induced by tumor necrosis factor and phorbol ester in colon cancer cells
53. Sodium butyrate inhibits expression of urokinase and its receptor mRNAs at both transcription and post-transcription levels in colon cancer cells
54. Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocyte-like U937 cells
55. Cytokine-specific regulation of urokinase receptor (CD87) expression by U937 mononuclear phagocytes
56. IFN-gamma, tumor necrosis factor-alpha, and urokinase regulate the expression of urokinase receptors on human monocytes
57. Endogenous receptor-bound urokinase mediates tissue invasion of human monocytes
58. Human mononuclear phagecyte activation antigens
59. Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor in human A549 lung carcinoma cells
60. Effect of thrombin, the thrombin receptor activation peptide, and mitogens on vascular smooth muscle cell urokinase receptor mRNA levels
61. Thrombin increases expression of urokinase receptor by activation of the thrombin receptor
62. Induction of differentiation of promyelocytic NB4 cells by retinoic acid is associated with rapid increase in urokinase activity subsequently downregulated by production of inhibitors
63. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells
64. A region between -141 and -61 bp containing a proximal AP-1 is essential for constitutive expression of urokinase-type plasminogen activator receptor
65. Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor
66. A conserved TATA-less proximal promoter drives basal transcription from the urokinase-type plasminogen activator receptor gene
67. Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene
68. Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade
69. Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires a JNK1-dependent signaling module
70. Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis
71. Transactivation of the urokinase-type plasminogen activator receptor gene through a novel promoter motif bound with an activator protein-2α-related factor
72. Regulation of urokinase receptor transcription by Ras- and Rho-family GTPases
73. Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma
74. Studies and perspectives of protein kinase C
75. Cross-linking of CD59 and of other glycosyl phosphatidylinositol-anchored molecules on neutrophils triggers cell activation via tyrosine kinase
76. Protein lipidation in cell signaling
77. Induction of cell migration by pro-urokinase binding to its receptor: Possible mechanism for signal transduction in human epithelial cells
78. Human urokinase-type plasminogen activator primes neutrophils for superoxide anion release. Possible roles of complement receptor type 3 and calcium
79. Interaction of urokinase-type plasminogenactivator (u-PA) with its cellular receptor (u-PAR) induces phosphorylation on tyrosine of a 38 kDa protein
80. Urokinase-type plasminogen activator stimulates the Ras/ERK signaling pathway and MCF-7 cell migration by a mechanism that requires FAK, Src, and Shc: Rapid dissociation of Grb2/Sos from Shc is associated with the transient phosphorylation of ERK in urokinase-treated cells
81. The urokinase-type plasminogen activator receptor, a GP[-linked protein, is localized in caveolae
82. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling
83. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function
84. Critical factors in the biology of human cancer metastasis
85. Cancer metastasis and angiogenesis, an imbalance of positive and negative regulation
86. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role
87. Molecular role(s) for integrins in human melanoma invasion
88. CD44 as a marker in human cancers
89. The urokinase-type plasminogen activator system in cancer metastasis: A review
90. Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1
91. Prevention of metastasis by inhibition of the urokinase receptor
92. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas
93. Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma
94. Cell surface expression of urokinase receptor in normal mammary epithelial cells and breast cancer cell lines
95. Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumors
96. Urokinase receptors in lung cancer and normal lung
97. Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma
98. Expression of urokinase-type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer
99. Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line
100. Prognostic impact of urokinase, urokinase receptor and type 1 plasminogen activator inhibitor in squamous- and large-cell lung-cancer tissue
101. Binding of urokinase to its receptor promoters migration and invasion of human melanoma cells in vitro
102. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model
103. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells
104. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography, comparison with urokinase levels
105. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression
106. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion
107. Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis
108. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas
109. Pooled analysis of uPA and PAI-1 for prognosis in primary breast cancer patients
110. Urokinase receptor and colorectal cancer survival
111. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression
112. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer
113. The urokinase system of plasminogen activation and prognosis in 2,780 breast cancer patients
114. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in colorectal cancer: Independent prognostic factors of metastasis and cancer specific survival, and potential therapeutic targets
115. Blockage of the urokinase receptor on the cell surface, construction and characterization of a hybrid protein consisting of the N-terminal fragment of human urokinase and human albumin
116. Saturation of tumor cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion
117. The role of the urokinase receptor in extracellular matrix degradation by HT29 human colon carcinoma cells
118. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA)
119. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy
120. Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger ODNs inhibition of urokinase receptor gene expression
121. Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth
122. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice
123. Inhibition of colon cancer metastasis by a 3′-end antisense uPAR mRNA in a nude mouse model
124. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation
125. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay